PRAX stock forecast, quote, news & analysis
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company... Show more
Why Praxis Precision Medicines (PRAX) Stock Is Up +24.5% in the Last 30 Days
Key Takeaways
- PRAX rose roughly 24.5% over the last 30 days, from a closing price of about $259.86 to approximately $323.59, including a single-session advance of about 16.6%.
- The move was fueled by analyst initiations and price-target increases, anticipation around the relutrigine regulatory decision, and a third-quarter update.
- Praxis Precision Medicines is a clinical-stage central nervous system (CNS) biotech focused on epilepsy and movement disorders, with four late-stage program candidates.
- Despite the recent rally, shares remain below their 52-week high of $392.70 and are still lower than early-August levels.
- Analyst consensus is a Strong Buy, with an average 12-month price target near $650, reflecting expectations tied to pipeline and regulatory catalysts.
- A key upcoming catalyst is the relutrigine PDUFA decision, scheduled for December 27.
- For additional detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated pages on Tickeron.
- To follow automated trading strategies across the broader market, explore Trending AI Robots.
Praxis Precision Medicines (PRAX) Company Overview and Market Position
Praxis Precision Medicines, Inc. is a Boston-based, clinical-stage biopharmaceutical company that develops precision therapies for central nervous system disorders driven by neuronal excitation-inhibition imbalance. The company applies insights from genetic epilepsies through two proprietary platforms: Cerebrum, a small-molecule engine for orally available precision medicines, and Solidus, an antisense oligonucleotide (ASO) platform.
Its most advanced programs include ulixacaltamide, a selective T-type calcium channel inhibitor under review for essential tremor with FDA Breakthrough Therapy Designation; relutrigine, a preferential sodium channel inhibitor in development for SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEE); vormatrigine, a sodium channel modulator in late-stage development for focal epilepsy; and elsunersen, an ASO being developed in collaboration with Ionis Pharmaceuticals for SCN2A-DEE. Investors follow PRAX closely because its diversified, multimodal pipeline targets both rare and more prevalent neurological conditions with significant unmet need.
Praxis Precision Medicines (PRAX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PRAX advanced approximately 24.5%, moving from a close of $259.86 to about $323.59. Much of that gain was concentrated around the company's third-quarter update, when the stock rose roughly 16.6% in a single session. The share price touched an intraday low near $239 in mid-October before recovering into November.
The last quarter tells a different story. After peaking near its 52-week high of $392.70 in mid-August, the stock entered a multi-week drawdown that pushed it down to roughly $239 by mid-October. Even with the recent rebound, PRAX remains roughly 12% below its early-August levels, underscoring the volatility typical of a high-beta, pre-commercial biotechnology name.
What Drove PRAX Stock Price in the Last 30 Days
Several verified factors contributed to the 30-day advance. Wall Street activity was a notable driver: UBS initiated coverage with a Buy rating and a $706 price target, JPMorgan initiated coverage with an Overweight rating and a $700 target, and BTIG raised its target to $826 from $810 while highlighting relutrigine's December 27 PDUFA date. Goldman Sachs also lifted its target to $575 from $470.
Momentum accelerated around the company's third-quarter 2026 results and corporate update. For the quarter ended September 30, 2026, Praxis reported a net loss of $94.23 million, compared with $73.93 million a year earlier, while diluted loss per share narrowed to $3.23 from $3.36. Investors appeared to focus less on the headline loss and more on the pipeline outlook, including the approaching relutrigine regulatory decision and continued advancement of ulixacaltamide toward a potential commercial launch.
What Drove PRAX Stock Performance Over the Last Quarter
The broader quarterly trend was defined by profit-taking and repositioning after a dramatic run-up. PRAX traded near all-time-high territory in August, reflecting enthusiasm across its late-stage CNS pipeline. From there, shares corrected steadily through September and into mid-October, a pattern consistent with a high-beta biotech consolidating after outsized gains rather than reacting to any single negative event.
Underlying the volatility are the same fundamentals investors have been tracking for months: a cash position sufficient to fund operations, multiple late-stage catalysts, and a consensus analyst view that remains constructive. The quarter illustrates how sentiment and positioning around binary clinical and regulatory events can outweigh near-term financial results for a pre-revenue developer.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots. Tickeron offers hundreds of automated trading bots that monitor thousands of tickers, but only the most relevant and consistently strong performers appear in this section. Each bot varies in strategy, timeframe, and performance metrics, giving traders a way to explore data-driven, algorithmically generated signals across different market conditions. For those interested in systematic approaches to navigating volatile names like PRAX, the page offers a starting point to review how these AI-driven strategies are performing.
PRAX Stock Forecast Drivers: What Investors Should Watch Next
The most consequential near-term event is the relutrigine PDUFA decision scheduled for December 27, which represents a binary catalyst for the stock. Beyond that, investors are likely to monitor continued progress on ulixacaltamide's regulatory path for essential tremor, data updates from the vormatrigine and elsunersen programs, and any additional analyst initiations or price-target revisions.
On the financial side, cash runway, spending trends, and the timing of potential commercialization efforts will remain in focus. As a pre-revenue clinical-stage company, PRAX carries elevated risk tied to clinical trial outcomes and regulatory decisions, and its high beta reflects significant price swings in response to news. Investors should weigh these catalysts and risks carefully rather than relying on short-term price momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for PRAX turns positive, indicating new upward trend
PRAX saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned positive. In 89 of the 96 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PRAX just turned positive on October 20, 2026. Looking at past instances where PRAX's MACD turned positive, the stock continued to rise in 41 of 43 cases over the following month. The odds of a continued upward trend are 90%.
PRAX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +21.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRAX advanced for three days, in 257 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for PRAX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
PRAX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PRAX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.780) is normal, around the industry mean (3.498). P/E Ratio (-21.421) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. PRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 85 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology